Evaluation of PK and Safety of D-0120 and Allopurinol

InventisBio

Status and phase: Completed; Early Phase 1

Conditions: Healthy

Treatments: Drug: D-0120 in combination with Allopurinol

Study type: Interventional

Funder types: Industry

Identifiers

NCT05360628

D0120-104

Details and patient eligibility

About

Evaluation of safety and PK interaction between D-0120 and Alopurinol in healthy adult subjects

Enrollment: 20 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy subjects between the ages of 18-55
• Required evaluation by Investigator for screening and enrollment
• Agreement and compliance with the study and follow-up procedures

Exclusion criteria

• Significant medical history or current comorbidly determined by the Investigator.
• Pregnant or nursing women

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

20 participants in 2 patient groups

D-0120 plus Allopurinol

Experimental group

Description:

D-0120 dosing followed by Allopurinol and combination treatment

Treatment:

Drug: D-0120 in combination with Allopurinol

Allopurinol plus D-0120

Experimental group

Description:

Allopurinol dosing followed by D-0120 and combination treatment

Treatment:

Drug: D-0120 in combination with Allopurinol